Recent Analysts’ Ratings Updates for iTeos Therapeutics (ITOS)

Several brokerages have updated their recommendations and price targets on shares of iTeos Therapeutics (NASDAQ: ITOS) in the last few weeks:

• 3/6/2025 – iTeos Therapeutics had its price target lowered by analysts at Wells Fargo & Company from $19.00 to $17.00. They now have an “overweight” rating on the stock.
• 3/6/2025 – iTeos Therapeutics had its price target lowered by analysts at JPMorgan Chase & Co. from $22.00 to $15.00. They now have an “overweight” rating on the stock.
• 3/6/2025 – iTeos Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
• 3/5/2025 – iTeos Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
• 1/16/2025 – iTeos Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.

iTeos Therapeutics Trading Down 3.5 %

NASDAQ:ITOS traded down $0.27 on Thursday, hitting $7.25. The company’s stock had a trading volume of 146,367 shares, compared to its average volume of 452,161. The stock has a fifty day moving average of $7.50 and a two-hundred day moving average of $9.20. iTeos Therapeutics, Inc. has a one year low of $6.67 and a one year high of $18.75. The firm has a market capitalization of $277.06 million, a P/E ratio of -2.30 and a beta of 1.38.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.13. As a group, sell-side analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. BVF Inc. IL bought a new stake in iTeos Therapeutics during the fourth quarter valued at approximately $17,856,000. JPMorgan Chase & Co. lifted its holdings in shares of iTeos Therapeutics by 342.7% in the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company’s stock worth $15,888,000 after buying an additional 1,601,477 shares during the period. Dimensional Fund Advisors LP grew its stake in iTeos Therapeutics by 15.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company’s stock valued at $9,293,000 after purchasing an additional 163,880 shares during the last quarter. State Street Corp lifted its holdings in shares of iTeos Therapeutics by 21.9% during the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company’s stock valued at $12,000,000 after purchasing an additional 211,452 shares during the last quarter. Finally, Boxer Capital Management LLC purchased a new stake in iTeos Therapeutics during the 4th quarter worth approximately $7,272,000. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.